The Patient Signal Titelbild

The Patient Signal

The Patient Signal

Von: Stan Berteloot
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

 Healthcare innovation is moving fast, but are we leaving the patient behind? The Patient Signal is the essential briefing for patient advocates, policymakers, and health tech innovators who need to understand the human impact of new technology. We move beyond the hype of funding rounds and stock prices to focus on what matters most: access, outcomes, and equity. Each episode breaks down the critical intersection of Artificial Intelligence, Life Sciences, and Government Policy. We filter the noise to find the specific tools and regulations that are changing the patient journey right now. If you are building the future of care or fighting for those who need it, this is your signal. What we cover: Health Policy: New CMS rulings and legislative updates affecting access. AI Innovation: Practical tools for diagnostics and remote care. Advocacy: Victories and challenges from the patient community.© 2026 Stan Berteloot Politik & Regierungen Wissenschaft
Folgen
  • Medtronic's Sphere-360 CE Mark, Parkinson's Precision Therapies, and BBB Breakthroughs

    Medtronic's Sphere-360 CE Mark, Parkinson's Precision Therapies, and BBB Breakthroughs
    Jan 27 2026
    In this episode, we explore Medtronic's recent CE mark approval for its Affera Sphere-360 pulsed field ablation catheter, designed to treat paroxysmal atrial fibrillation. This innovative device offers a competitive edge by ablating target tissue without rotation, contributing to a significant surge in Medtronic's PFA sales and supporting their strategy to enhance profit margins. Next, we delve into the advancements in Parkinson's disease treatment, highlighting investigational therapies targeting underlying mechanisms. Companies like Ventyx Therapeutics, AC Immune, Gain Therapeutics, Denali Therapeutics, and Biogen are pioneering precision medicine approaches to develop more effective treatments. Moving on, we discuss the challenges and breakthroughs in overcoming the Blood-Brain Barrier (BBB) for neurological disease treatment. Innovations in antibody technology, such as Receptor-Mediated Transcytosis and bispecific antibodies, are paving the way for effective drug delivery across the BBB, promising a transformation in brain disease treatment. Meanwhile, the clinical diagnostics sector is set for significant advancements by 2026, driven by technological innovations and data integration. The rise of AI, machine learning, and wearable devices is expected to enhance diagnostic accuracy, speed, and accessibility, empowering patients and healthcare providers alike. On that note, nearly 30,000 COPD patients in England may soon benefit from Dupixent, a biologic treatment by Sanofi and Regeneron, following NHS recommendation. This targeted therapy aims to reduce flare-ups and improve lung function, potentially saving the NHS millions annually. Finally, researchers from New England Biolabs and Yale University have developed a synthetic bacteriophage engineering system to combat antibiotic resistance. This innovative approach simplifies phage engineering, offering a promising solution against multi-drug resistant bacteria like Pseudomonas aeruginosa. Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today! Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today! 📚 Sources: https://www.medtechdive.com/news/medtronic-wins-ce-mark-for-single-shot-pulsed-field-ablation-catheter/810448/https://www.biospace.com/drug-development/5-investigational-therapies-that-could-change-the-parkinsons-landscapehttps://www.biospace.com/press-releases/overcoming-the-wall-how-far-has-bbb-crossing-antibody-technology-truly-advanced-commentary-by-unexakoreahttps://www.fiercehealthcare.com/sponsored/whats-next-clinical-diagnostics-2026https://pharmaphorum.com/news/copd-patients-will-get-access-dupixent-nhshttps://www.genengnews.com/topics/infectious-diseases/antibiotic-resistance-combatted-by-fully-synthetic-bacteriophage-assembly
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Integra Recall, Curant-Cencora Partnership, AION Labs AI, NICE DHTs, Cellular Origins Update

    Integra Recall, Curant-Cencora Partnership, AION Labs AI, NICE DHTs, Cellular Origins Update
    Jan 26 2026

    In this episode, we cover several significant developments in the healthcare and pharmaceutical industries. Integra LifeSciences has recalled certain wound and burn treatment devices due to packaging failures that could lead to infections, with 14 serious injuries reported. Curant Rare and Cencora have partnered to streamline the commercialization of rare disease therapies, aiming to overcome regulatory and access challenges. AION Labs is advancing drug discovery by integrating AI and quantum technologies, positioning itself at the forefront of innovation. IQVIA is enhancing clinical research with Agentic AI, improving trial efficiency and accuracy. NICE has approved digital health technologies for NHS use to support individuals with osteoarthritis and bulimia, aligning with digital transformation goals. Cellular Origins and Fresenius Kabi are collaborating to automate cell and gene therapy manufacturing, reducing costs and manual intervention. We also discuss the importance of intersectionality in healthcare workforces, the integration of AI in medicine, and the foundational elements of health disparities science.

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

    As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

    Start your VoiceStream free trial today!

    Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today!

    📚 Sources:
    • https://www.medtechdive.com/news/integra-recalls-wound-burn-devices-medihoney/810323/
    • https://www.biospace.com/press-releases/curant-rare-announces-collaboration-with-cencora-to-support-commercialization-of-rare-and-orphan-drug-products
    • https://www.mobihealthnews.com/video/using-quantum-technology-drug-discovery
    • https://www.appliedclinicaltrialsonline.com/view/the-key-to-clinical-trial-success-patient-tokenization
    • https://pharmaphorum.com/news/digital-osteoarthritis-bulimia-tools-backed-nhs-use
    • https://www.genengnews.com/topics/bioprocessing/milestone-reached-in-cell-and-gene-therapy-robotic-automation-and-manufacturing-collaboration/
    • https://www.thelancet.com/pdfs/journals/lanam/PIIS2667-193X(24)00300-4.pdf
    • https://ai.nejm.org/doi/full/10.1056/AIe2300197
    • https://jamanetwork.com/journals/jama-health-forum/fullarticle/2812750
    Mehr anzeigen Weniger anzeigen
    10 Min.
  • Dawnzera's EU Approval, Medtronic's Investment in Anteris, and DEI Trends in Life Sciences

    Dawnzera's EU Approval, Medtronic's Investment in Anteris, and DEI Trends in Life Sciences
    Jan 22 2026
    In this episode, we explore the latest developments in the healthcare and pharmaceutical industries. The European Commission has approved Otsuka's Dawnzera for preventing recurrent attacks in hereditary angioedema, a rare disease, marking a significant advancement in treatment options. Medtronic plans a substantial investment in Anteris Technologies, contingent on a successful public stock offering, to support the development of the DurAVR aortic heart valve. Meanwhile, life sciences companies are increasingly rejecting proposals against diversity, equity, and inclusion initiatives, recognizing their strategic importance. Anamika Shrimali shares her experience with the HPV vaccine, highlighting the need for better vaccine accessibility and awareness. Mayo Clinic's Ugur Sener and Taylor Galloway introduce an innovative approach to brain cancer care through the Neuro-Oncology Anywhere clinical trial portfolio. Taconic Biosciences enhances its research capabilities by acquiring TransCure bioServices, strengthening its platform for humanized mouse translational research. In other news, GE HealthCare and Epic Systems navigate challenges in AI investment and antitrust allegations, while health insurance executives face congressional scrutiny. Finally, the evolution of global trial strategies is reshaping clinical research, emphasizing collaboration and technological integration to enhance patient care and medical advancements. Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today! Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today! 📚 Sources: https://pharmaphorum.com/news/eu-approves-otsukas-long-acting-hae-drug-dawnzerahttps://www.medtechdive.com/news/medtronic-buy-up-to-90m-stake-heart-valve-anteris/810110/https://www.appliedclinicaltrialsonline.com/view/business-case-dei-pharmaceutical-innovation-organizational-commitment-inclusive-clinical-trialshttps://www.statnews.com/2026/01/21/what-psa-screening-gets-wrong-prostate-cancer/https://www.mobihealthnews.com/news/mayo-clinic-rethinking-brain-cancer-care-digital-transformationhttps://www.biospace.com/press-releases/taconic-biosciences-acquires-transcure-bioservices-building-a-comprehensive-global-platform-for-humanized-mouse-translational-researchhttps://www.modernhealthcare.com/events/mh-roi-profitability-playbook-parminder-bhatia-ge-healthcare/https://www.appliedclinicaltrialsonline.com/view/life-sciences-dei-startup-timelines-regulators-align-ai-governance
    Mehr anzeigen Weniger anzeigen
    9 Min.
Noch keine Rezensionen vorhanden